Drugs of abuse public hearing
This article was originally published in The Gray Sheet
Input on a March 5 proposed rule to downclassify from Class III to Class I over-the-counter urine sample collection systems for drugs-of-abuse testing will be sought at a June 19 meeting in Rockville, Maryland. William Schultz, FDA deputy commissioner for policy, will direct the meeting. For more information contact the device center's Steven Gutman at 301/594-3084
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.